Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer

[1]  Y. Huang,et al.  14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling , 2018, Journal of experimental & clinical cancer research : CR.

[2]  R. Hass,et al.  Enhanced metastatic capacity of breast cancer cells after interaction and hybrid formation with mesenchymal stroma/stem cells (MSC) , 2018, Cell Communication and Signaling.

[3]  R. Hass,et al.  Enhanced metastatic capacity of breast cancer cells after interaction and hybrid formation with mesenchymal stroma/stem cells (MSC) , 2018, Cell Communication and Signaling.

[4]  E. Chan,et al.  Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy , 2017, Biochemical pharmacology.

[5]  K. Lee,et al.  Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions , 2017, Front. Pharmacol..

[6]  Jing Wang,et al.  WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit , 2017, Nucleic Acids Res..

[7]  M. Seo,et al.  IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells , 2016, BMC Cancer.

[8]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[9]  S. Manalis,et al.  Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. , 2016, Developmental cell.

[10]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[11]  L. Shyur,et al.  Simvastatin and a Plant Galactolipid Protect Animals from Septic Shock by Regulating Oxylipin Mediator Dynamics through the MAPK-cPLA2 Signaling Pathway , 2015, Molecular medicine.

[12]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[13]  J. Koo,et al.  Differential Expression of Lipid Metabolism-Related Proteins in Different Breast Cancer Subtypes , 2015, PloS one.

[14]  Rodney J Scott,et al.  Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value , 2015, Nature Communications.

[15]  M. Hallett,et al.  Absolute assignment of breast cancer intrinsic molecular subtype. , 2015, Journal of the National Cancer Institute.

[16]  Xiaolong Wei,et al.  Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer , 2014, BMC Cancer.

[17]  E. Iversen,et al.  A joint analysis of metabolomics and genetics of breast cancer , 2014, Breast Cancer Research.

[18]  Renu Malhotra,et al.  IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples , 2014, PloS one.

[19]  S. Lakhani,et al.  Rad51 supports triple negative breast cancer metastasis , 2014, Oncotarget.

[20]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Richard D. Beger,et al.  A Review of Applications of Metabolomics in Cancer , 2013, Metabolites.

[22]  Bing Zhang,et al.  NetGestalt: integrating multidimensional omics data over biological networks , 2013, Nature Methods.

[23]  Jing Wang,et al.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 , 2013, Nucleic Acids Res..

[24]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[25]  Michal Sheffer,et al.  Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.

[26]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[27]  Dexter T. Duncan,et al.  GLAD4U: deriving and prioritizing gene lists from PubMed literature , 2012, BMC Genomics.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[29]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[30]  Marc E. Lenburg,et al.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.

[31]  Donald E Ingber,et al.  Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. , 2012, The Journal of clinical investigation.

[32]  Sui Huang,et al.  Regulation of inflammation in cancer by eicosanoids. , 2011, Prostaglandins & other lipid mediators.

[33]  Matej Oresic,et al.  Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. , 2011, Cancer research.

[34]  E. Schuetz,et al.  CYP3A4 Mediates Growth of Estrogen Receptor-positive Breast Cancer Cells in Part by Inducing Nuclear Translocation of Phospho-Stat3 through Biosynthesis of (±)-14,15-Epoxyeicosatrienoic Acid (EET)* , 2011, The Journal of Biological Chemistry.

[35]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[36]  D. Zeldin,et al.  Cytochrome P450 2J2 Is Highly Expressed in Hematologic Malignant Diseases and Promotes Tumor Cell Growth , 2011, Journal of Pharmacology and Experimental Therapeutics.

[37]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[38]  Jorge S Reis-Filho,et al.  Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry , 2010, Breast Cancer Research.

[39]  Sui Huang,et al.  Cytochrome P450-derived eicosanoids: the neglected pathway in cancer , 2010, Cancer and Metastasis Reviews.

[40]  Charles M Perou,et al.  Clinical implementation of the intrinsic subtypes of breast cancer. , 2010, The Lancet. Oncology.

[41]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[42]  Caroline A. Lee,et al.  Identification of Novel Substrates for Human Cytochrome P450 2J2 , 2010, Drug Metabolism and Disposition.

[43]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[44]  C. Ingvar,et al.  CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients , 2009, British Journal of Cancer.

[45]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[46]  R. Totah,et al.  Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology , 2009, Expert opinion on drug metabolism & toxicology.

[47]  K. Thummel.  Gut instincts: CYP3A4 and intestinal drug metabolism. , 2007, The Journal of clinical investigation.

[48]  Louise R Howe,et al.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.

[49]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[50]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[51]  Baolin Zhang,et al.  Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis* , 2006, Journal of Biological Chemistry.

[52]  D. Zeldin,et al.  Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. , 2005, Cancer research.

[53]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[54]  D. Zeldin.  Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.